A Rare Case of Henoch-Schönlein Purpura Following a COVID-19 Vaccine—Case Report
Abstract In the COVID-19 pandemic era, anti-SARS-CoV-2 vaccination is considered to be the most efficient way to overtake the COVID-19 scourge. Like all medicines, vaccines are not devoid of risks and can in rare cases cause some various side effects. The objective of this case report is to highlight this unusual presentation of Henoch-Schönlein purpura following an anti-COVID-19 vaccination in a 62-year-old adult. The 62-year-old patient admitted to the emergency room for a petechial purpuric rash, sloping, occurring within hours, involving both legs and ascending. The clinical signs also included polyarthralgia and hematuria. Reported in the history the notion of an anti-COVID-19 vaccination 8 days prior to the onset of symptomatology. In the case of our patient, we retain the diagnosis of rheumatoid purpura based on the EULAR/PRINTO/PReS diagnostic criteria. Corticosteroid therapy (prednisone) was started, resulting to a rapid regression of clinical and laboratory symptoms, few days after the treatment. Patient was asymptomatic on subsequent visits. The low number of published cases of post-vaccine vasculitis does not question the safety of vaccines, but knowledge of such complications deserves to be known in order to avoid new immunizations that could have more serious consequences, and to avoid aggravating or reactivating a pre-existing vasculitis..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:3 |
---|---|
Enthalten in: |
SN comprehensive clinical medicine - 3(2021), 12 vom: 08. Sept., Seite 2618-2621 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Naitlho, Abdelhamid [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
Anti-SARS-CoV-2 vaccine |
---|
Anmerkungen: |
© The Author(s) 2021 |
---|
doi: |
10.1007/s42399-021-01025-9 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR045715882 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR045715882 | ||
003 | DE-627 | ||
005 | 20230519155842.0 | ||
007 | cr uuu---uuuuu | ||
008 | 211202s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s42399-021-01025-9 |2 doi | |
035 | |a (DE-627)SPR045715882 | ||
035 | |a (SPR)s42399-021-01025-9-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q ASE |
082 | 0 | 4 | |a 610 |q ASE |
100 | 1 | |a Naitlho, Abdelhamid |e verfasserin |4 aut | |
245 | 1 | 2 | |a A Rare Case of Henoch-Schönlein Purpura Following a COVID-19 Vaccine—Case Report |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s) 2021 | ||
520 | |a Abstract In the COVID-19 pandemic era, anti-SARS-CoV-2 vaccination is considered to be the most efficient way to overtake the COVID-19 scourge. Like all medicines, vaccines are not devoid of risks and can in rare cases cause some various side effects. The objective of this case report is to highlight this unusual presentation of Henoch-Schönlein purpura following an anti-COVID-19 vaccination in a 62-year-old adult. The 62-year-old patient admitted to the emergency room for a petechial purpuric rash, sloping, occurring within hours, involving both legs and ascending. The clinical signs also included polyarthralgia and hematuria. Reported in the history the notion of an anti-COVID-19 vaccination 8 days prior to the onset of symptomatology. In the case of our patient, we retain the diagnosis of rheumatoid purpura based on the EULAR/PRINTO/PReS diagnostic criteria. Corticosteroid therapy (prednisone) was started, resulting to a rapid regression of clinical and laboratory symptoms, few days after the treatment. Patient was asymptomatic on subsequent visits. The low number of published cases of post-vaccine vasculitis does not question the safety of vaccines, but knowledge of such complications deserves to be known in order to avoid new immunizations that could have more serious consequences, and to avoid aggravating or reactivating a pre-existing vasculitis. | ||
650 | 4 | |a Rheumatoid purpura |7 (dpeaa)DE-He213 | |
650 | 4 | |a Henoch-Schönlein purpura |7 (dpeaa)DE-He213 | |
650 | 4 | |a Anti-SARS-CoV-2 vaccine |7 (dpeaa)DE-He213 | |
650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
650 | 4 | |a Post-vaccinal vasculitis |7 (dpeaa)DE-He213 | |
650 | 4 | |a Vaccine secondary effects |7 (dpeaa)DE-He213 | |
700 | 1 | |a Lahlou, Wahib |e verfasserin |4 aut | |
700 | 1 | |a Bourial, Abderrahim |e verfasserin |4 aut | |
700 | 1 | |a Rais, Hamza |e verfasserin |4 aut | |
700 | 1 | |a Ismaili, Nabil |e verfasserin |4 aut | |
700 | 1 | |a Abousahfa, Imad |e verfasserin |4 aut | |
700 | 1 | |a Belyamani, Lahcen |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t SN comprehensive clinical medicine |d [Cham] : Springer International Publishing, 2019 |g 3(2021), 12 vom: 08. Sept., Seite 2618-2621 |w (DE-627)SPR038535785 |w (DE-600)2947252-0 |x 2523-8973 |7 nnns |
773 | 1 | 8 | |g volume:3 |g year:2021 |g number:12 |g day:08 |g month:09 |g pages:2618-2621 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s42399-021-01025-9 |z kostenfrei |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |d 3 |j 2021 |e 12 |b 08 |c 09 |h 2618-2621 |